Most monkeypox concept stocks have risen, as of press time, Virax Biolabs has risen nearly 190%.
According to the Intelligent Finance and Economics App, on Monday, most monkeypox concept stocks have risen. As of press time, Virax Biolabs (VRAX.US) has risen nearly 190%, Applied DNA Sciences (APDN.US) has risen nearly 130%, Tonix Pharmaceuticals (TNXP.US) has risen nearly 50%, Geovax Labs (GOVX.US) has risen more than 29%, Co-Diagnostics (CODX.US) has risen nearly 18%, Chimerix (CMRX.US) has risen 0.02%; Siga Technologies (SIGA.US) has fallen more than 5.8%, and Emergent Biosolutions (EBS.US) has fallen more than 1.2%. On the news front, the Philippine health department announced on Monday that a new case of monkeypox virus infection has been found in the Philippines, the country's first case since December last year. Earlier, the latest cases of monkeypox infection had been found in Sweden and Pakistan.
Since the beginning of this year, the number of suspected or confirmed monkeypox cases reported in Africa has exceeded the total number of cases last year. On August 14, the Director-General of the World Health Organization declared that the monkeypox epidemic constitutes a public health emergency of international concern, and subsequently, monkeypox concept stocks in the U.S. have continued to rise.
